Positron Emission Tomography (PET) radiotracers in oncology – utility of 18F-Fluoro-deoxy-glucose (FDG)-PET in the management of patients with non-small-cell lung cancer (NSCLC)
2008

The Role of PET Scans in Managing Non-Small Cell Lung Cancer

publication Evidence: moderate

Author Information

Author(s): Evelina Miele, Gian Paolo Spinelli, Federica Tomao, Angelo Zullo, Filippo De Marinis, Giulia Pasciuti, Luigi Rossi, Federica Zoratto, Silverio Tomao

Primary Institution: Department of Experimental Medicine University of Rome 'Sapienza'

Hypothesis

How effective are PET radiotracers, particularly 18F-FDG, in the management of non-small cell lung cancer?

Conclusion

PET scans, especially with 18F-FDG, are crucial for diagnosing, staging, and monitoring treatment responses in non-small cell lung cancer.

Supporting Evidence

  • FDG-PET is more sensitive than traditional imaging for assessing treatment response.
  • PET scans can help avoid unnecessary surgeries by accurately staging lung cancer.
  • Integrated PET-CT improves the accuracy of staging compared to PET alone.

Takeaway

PET scans help doctors see how cancer is behaving in the body, which helps them decide the best way to treat it.

Methodology

This review discusses the use of various PET radiotracers, focusing on their application in non-small cell lung cancer diagnosis and treatment.

Potential Biases

Potential biases may arise from the selection of studies included in the review and the interpretation of their results.

Limitations

The review does not provide specific data on the effectiveness of each tracer or the variability in results across different studies.

Digital Object Identifier (DOI)

10.1186/1756-9966-27-52

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication